Bioptix (BIOP) Earning Somewhat Favorable Press Coverage, Report Finds

News headlines about Bioptix (NASDAQ:BIOP) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioptix earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the technology company an impact score of 44.363935756927 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Bioptix (NASDAQ BIOP) traded down 2.16% during trading on Friday, reaching $3.62. The company’s stock had a trading volume of 2,757 shares. The company’s market cap is $15.96 million. The company’s 50 day moving average price is $3.81 and its 200 day moving average price is $3.68. Bioptix has a 52 week low of $3.02 and a 52 week high of $4.80.

COPYRIGHT VIOLATION NOTICE: This news story was published by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at

Bioptix Company Profile

Bioptix, Inc, formerly Venaxis, Inc, provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered.

Receive News & Ratings for Bioptix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioptix Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply